Fulcrum Therapeutics
NASDAQ: FULCCambridge, US · Founded 2015 · Delaware corporation · 2 known investors
Find your way into Fulcrum Therapeutics
Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.
Founders & leadership
RG
Robert GouldinExecutive
AC
Alex C. SapirinPresident and Chief Executive Officer, DirectorAlex Sapir brings over 20 years of pharmaceutical industry experience, including roles as President and CEO of Dova Pharmaceuticals—where he led the company through an IPO and growth to 150 employees with marketed products—and Executive Vice President of Marketing and Sales at United Therapeutics, where he oversaw expansion from one to five products generating $1.6 billion in annual revenue. He holds a BA in Economics from Franklin and Marshall College and an MBA from Harvard Business School, and previously taught marketing strategy as an adjunct professor at Loyola University.
Board
AE
ML
JG
James GeraghtyBoard director
JC
James CollinsBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$183.2M disclosed across 4 rounds · 2016–2020
▶$68.5MraisedJun 2020 · 13 investors · BiotechnologyRule 506(b)
▶$68.5MraisedJun 2020 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark LevinDirector
- James GeraghtyDirector
- Diego CadavidExecutive Officer
- Kate HavilandDirector
- James CollinsDirector
- Katina DortonDirector
- Robert GouldExecutive Officer, Director
- Bryan StuartExecutive Officer
- Owen WallaceExecutive Officer
- Alan EzekowitzDirector
- Offering amount
- $68.5M
- Amount sold
- $68.5M
- Sales commissions
- $4.1M
- Placement agents
- SVB Leerink LLC
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$80MraisedSep 2018 · 20 investors · BiotechnologyRule 506(b)
▶$80MraisedSep 2018 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James GeraghtyDirector
- Alan EzekowitzDirector
- Kate HavilandDirector
- James CollinsDirector
- Mark LevinDirector
- James TananbaumDirector
- Amit HasijaExecutive Officer
- Robert GouldExecutive Officer, Director
- Owen WallaceExecutive Officer
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$29.7MraisedJul 2017 · 1 investors · BiotechnologyRule 506(b)
▶$29.7MraisedJul 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan EzekowitzDirector
- Robert GouldExecutive Officer, Director
- James GeraghtyDirector
- James CollinsDirector
- Mark LevinDirector
- Offering amount
- $55M
- Amount sold
- $29.7M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$5MraisedMay 2017 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedMay 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan EzekowitzDirector
- James CollinsDirector
- Mark LevinDirector
- Robert GouldExecutive Officer, Director
- James GeraghtyDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsfiercebiotech.com · Aug 2026
Kaplan Fox Launches Securities Probe into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Haltkalkinemedia.com · Aug 2026Frequently asked questions
- What does Fulcrum Therapeutics do?
- Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.
- Who are Fulcrum Therapeutics's investors?
- Fulcrum Therapeutics's investors include Foresite Capital, Third Rock Ventures.
- How much funding has Fulcrum Therapeutics raised?
- Fulcrum Therapeutics has disclosed $183.2M raised across 4 rounds.
- Where is Fulcrum Therapeutics headquartered?
- Fulcrum Therapeutics is headquartered in Cambridge, US.